Menu Search
Equities

Adlai Nortye Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
N2U0:FRA

Adlai Nortye Ltd

Actions
  • Price (EUR)7.65
  • Today's Change-0.10 / -1.29%
  • Shares traded35.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Feb 16 2026 14:25 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Adlai Nortye Ltd. is a Cayman Islands-based investment holding company. The Company is involved in the research and development of pharmaceutical products. It is a clinical-stage company focused on the development of targeted and immune-modulating cancer therapies. It is advancing an oncology pipeline, with Buparlisib (AN2025), a pan-phosphoinositide 3-kinase (PI3K) inhibitor, being evaluated in a registrational Phase three trial (NCT04338399) for patients with recurrent or metastatic head and neck squamous cell cancer (HNSCC) that has progressed after prior anti-programmed death-ligand 1 (PD-L1) treatment. It is also advancing multiple drug candidates, including AN4005, an oral small molecule PD-L1 inhibitor; AN8025, a multifunctional fusion protein acting as a T cell and antigen-presenting cell (APC) modulator; and AN9025, an oral small molecule pan-rat sarcoma virus (RAS) inhibitor. The Company’s subsidiary, Alpine Bioscience Ltd. (Alpine BVI), is an investment holding company.

  • Revenue in USD (TTM)0.00
  • Net income in USD-42.59m
  • Incorporated2018
  • Employees123.00
  • Location
    Adlai Nortye Ltdc/o Ugland HousePO Box 309GRAND CAYMAN KY1-1104Cayman IslandsCYM
  • Phone+1 8 482307430
  • Websitehttps://www.adlainortye.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.